Postmenopausal women with early-stage BC/low recurrence score could skip adjuvant chemo

December 09, 2020

SAN ANTONIO - After a median follow-up of 5.1 years, among women with lymph node-positive early-stage breast cancer and a recurrence score of 25 or lower who received adjuvant endocrine therapy with or without chemotherapy, postmenopausal patients had no added benefit from chemotherapy, while premenopausal patients who received chemotherapy had improved invasive disease-free survival (IDFS) and an early indication of improved overall survival (OS), according to data from the SWOG S1007 RxPONDER clinical trial presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11.

"The most common form of breast cancer is hormone receptor (HR)-positive and HER2-negative, comprising about two-thirds of all invasive breast cancers," said Kevin Kalinsky, MD, MS, director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University.

RxPONDER was designed and run by SWOG Cancer Research Network with support from the National Cancer Institute. It set out to determine which patients with HR-positive, HER2-negative breast cancer and one to three positive axillary lymph nodes benefit from chemotherapy and which patients could safely avoid chemotherapy and still achieve similar outcomes with endocrine therapy alone, Kalinsky said. "Up until now, there were no data from a large randomized clinical trial to guide this decision," he added.

"At the time of this analysis, our data show that postmenopausal women with HR-positive, HER2-negative breast cancer with one to three positive nodes and a recurrence score of 25 or lower can safely avoid receiving adjuvant chemotherapy. On the other hand, premenopausal patients with HR-positive, HER2-negative breast cancer with one to three positive nodes and a recurrence score of 25 or lower should consider adjuvant chemotherapy. The invasive disease-free survival rate improved by 5 percent with chemotherapy in this group," Kalinsky said.

In this clinical trial, 5,083 patients with stage 2-3 breast cancer involving one to three axillary lymph nodes and whose tissue had a recurrence score of 25 or lower were randomly assigned (1:1) to endocrine therapy alone or endocrine therapy plus chemotherapy. Roughly two-thirds of the patients were postmenopausal. Data were stratified by recurrence score (0-13 versus 14-25), menopausal status, and axillary nodal dissection versus sentinel node biopsy.

The recurrence score, which can range from zero to 100, was determined using the Oncotype Dx test. The test provides a genome-based individualized risk assessment (by evaluating 16 cancer-related genes) for early-stage invasive breast cancer.

The study was designed to assess whether the difference in IDFS for patients treated with chemotherapy, compared with no chemotherapy, was related to the recurrence score. The investigators found no association between chemotherapy benefit and recurrence score values between 0-25 when evaluating the entire study population including both premenopausal and postmenopausal women.

However, there was a significant association between chemotherapy benefit and menopausal status, triggering further analyses of the data by menopausal status.

In postmenopausal patients with recurrence scores of 25 or lower, there was no difference in the five-year IDFS between those who received chemotherapy and those who did not (91.6 percent vs. 91.9 percent, respectively).

In premenopausal patients with recurrence scores of 25 or lower, five-year IDFS was 94.2 percent for those who received chemotherapy, versus 89 percent for those who did not receive chemotherapy. Data also showed a 53 percent OS benefit in premenopausal patients, although this result is considered early due to the limited number of events at the time of evaluation. The results were similar in premenopausal women with recurrence scores 0-13 and those with recurrence scores 14-25.

"For premenopausal patients with node-positive breast cancer, we know from other studies that the most effective adjuvant endocrine therapy is ovarian suppression combined with an aromatase inhibitor. We also know that chemotherapy induces ovarian suppression that is often permanent in premenopausal women," explained Kalinsky.

Among the premenopausal women in this study, ovarian suppression was performed in 15.9 percent of those in the endocrine therapy alone arm, versus in 3.7 percent of those in the chemotherapy plus endocrine therapy arm. "To what extent the chemotherapy benefit observed in our trial is due to chemotherapy-induced menopause remains unknown," Kalinsky noted.

"We are reporting these data at 53.7 percent of expected IDFS events. We will continue to report updates from this study as more follow-up data are collected," he said.

Limitations of the study include that these data represent an interim analysis. Future studies will allow for additional subset data analyses and time for continued follow-up, Kalinsky said.
-end-
This study was sponsored by the National Cancer Institute and in part by Susan G. Komen for the Cure Research Program, The Hope Foundation for Cancer Research, Breast Cancer Research Foundation, and Exact Sciences.

Kalinsky reports research support from Immunomedics Inc., Novartis, Incyte, Genentech/Roche, Eli Lilly, Pfizer, Calithera Biosciences, Acetylon, Seattle Genetics, Amgen, Zentalis Pharmaceuticals, and CytomX Therapeutics; has served as a consultant to Immunomedics, Biotheranostics, Pfizer, Novartis, Eisai, Eli Lilly, Amgen, Merck, Seattle Genetics, and Astra Zeneca.

About the San Antonio Breast Cancer Symposium

Since 1977, the San Antonio Breast Cancer Symposium® (SABCS®) has been the leading scientific conference for basic scientists, physician-scientists, clinical investigators and breast care providers, and advocates seeking an exchange of new information in experimental biology, etiology, prevention, diagnosis, and therapy of premalignant breast disease and breast cancer. Founded, owned, and operated by UT Health San Antonio, the symposium has grown to a five-day event attended by an international audience of academic investigators and private physicians from over 80 countries to attain information through abstract presentations, panel discussions, research findings, and state-of-the-art educational sessions. UT Health San Antonio, with co-sponsors the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine and the American Association for Cancer Research, supports SABCS, which provides education and accessibility to the latest information regarding the prevention, diagnosis, and treatment of premalignant breast cancer and breast disease. For more information on SABCS, visit http://www.sabcs.org.

To interview Kevin Kalinsky, please contact Julia Gunther at julia.gunther@aacr.org or 770-403-7690.

American Association for Cancer Research

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.